AVDL AVADEL PHARMACEUTICALS PLC Product Launches 8-K Filing 2024 - Product Launch Avadel Pharmaceuticals announced the dosing of the first patient in the Phase 3 REVITALYZ trial of LUMRYZ for the treatment of Idiopathic Hypersomnia.Get access to all SEC 8-K filings of the AVADEL PHARMACEUTICALS PLC